NASDAQ:CABA
Cabaletta Bio, Inc. Stock News
$12.35
-0.270 (-2.14%)
At Close: May 17, 2024
Are Medical Stocks Lagging Cabaletta Bio (CABA) This Year?
11:17am, Monday, 09'th Oct 2023
Here is how Cabaletta Bio, Inc. (CABA) and KalVista Pharmaceuticals, Inc. (KALV) have performed compared to their sector so far this year.
What Makes Cabaletta Bio, Inc. (CABA) a Good Fit for 'Trend Investing'
10:31am, Monday, 25'th Sep 2023
Cabaletta Bio, Inc. (CABA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed th
Cabaletta Bio to Participate in Upcoming Investor Conferences in September
08:00am, Tuesday, 19'th Sep 2023
PHILADELPHIA, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapi
Cabaletta Bio: How Long Can Unique Cell Therapy Developer's Sensational Bull Run Continue?
04:56am, Tuesday, 19'th Sep 2023
Cabaletta Bio stock has experienced a significant bull run, rising over 2,100% in the past year. The company's focus on autoimmune conditions with a validated cell therapy approach, rather than oncolo
Cabaletta Bio, Inc. (CABA) is on the Move, Here's Why the Trend Could be Sustainable
10:32am, Friday, 08'th Sep 2023
Cabaletta Bio, Inc. (CABA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed th
The 7 Most Promising Momentum Stocks to Own Now
08:30am, Thursday, 31'st Aug 2023
Today's volatile market makes momentum investing a compelling strategy for those comfortable with daily turbulence. Unlike value investing, which is rooted in purchasing undervalued assets, momentum i
Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in September
08:00am, Wednesday, 30'th Aug 2023
PHILADELPHIA, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapie
Recent Price Trend in Cabaletta Bio, Inc. (CABA) is Your Friend, Here's Why
10:32am, Wednesday, 23'rd Aug 2023
If you are looking for stocks that are well positioned to maintain their recent uptrend, Cabaletta Bio, Inc. (CABA) could be a great choice. It is one of the several stocks that passed through our "Re
Does Cabaletta Bio, Inc. (CABA) Have the Potential to Rally 27.85% as Wall Street Analysts Expect?
03:27pm, Tuesday, 15'th Aug 2023
The average of price targets set by Wall Street analysts indicates a potential upside of 27.9% in Cabaletta Bio, Inc. (CABA). While the effectiveness of this highly sought-after metric is questionable
Why Shares of Cabaletta Bio Are Up Tuesday
02:58pm, Tuesday, 18'th Jul 2023
The clinical-stage biotech has seven programs in its pipeline. Cabaletta focuses on therapies to treat autoimmune disorders.
Why Is Cabaletta Bio (CABA) Stock Down 8% Today?
09:27am, Wednesday, 21'st Jun 2023
Cabaletta Bio (NASDAQ: CABA ) stock is falling on Wednesday following news of insider selling at the targeted cell therapy company. Gwendolyn Binder, the President of Science and Technology at Cabalet
TipRanks reveals the top 10 health care sector analysts of the past decade
08:20am, Sunday, 21'st May 2023
TipRanks' analyst ranking service ranks the top Wall Street firms of the past decade.
Cabaletta Bio to Present at the American Society of Gene and Cell Therapy 26th Annual Meeting
04:35pm, Tuesday, 02'nd May 2023
PHILADELPHIA, May 02, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies
Cabaletta Bio to Present at the 22nd Annual Needham Virtual Healthcare Conference
04:30pm, Thursday, 13'th Apr 2023
PHILADELPHIA, April 13, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapi
